Crafting a genomics strategy early is key for successful oncology drug development

May 28, 2019

An historic shift towards treating cancer based on a tumor’s genetics rather than its site of origin is underway. Genomically-targeted drugs, properly developed, have an inherent advantage over drugs that are not. But the success of any one will depend on good strategic planning, done early. Read about three key considerations for crafting a successful genomic biomarker strategy.

Previous Article
Hong Kong Exchange: Nurturing China’s Biotech Valley
Hong Kong Exchange: Nurturing China’s Biotech Valley

About the Authors Daniel Huang is an Analyst based in the Hong Kong...

Next Article
eBook: Biopharma in the COVID-19 World
eBook: Biopharma in the COVID-19 World